ClinicalTrials.gg
CompletedNCT00325390Updated Mar 25, 2009

Efficacy and Safety in Patients With Acute Coronary Syndrome Without ST-Segment Elevation

A Phase 3 interventional study of clopidogrel (SR25990C) in Platelet Aggregation Inhibitors and NSTEACS, sponsored by Sanofi. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2009-03-25.

Sponsored by Sanofi · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
800
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

To evaluate the efficasy and safety of SR25990C(loading dose:300mg, maintenance dose:75mg/day) in comparison with the standard Japanese treatment(ticlopidine) in patients with acute coronary syndrome without ST-segment elevation and planned for percutaneous coronary intervention(including stenting).

02

Conditions studied

  • Platelet Aggregation Inhibitors
  • NSTEACS

Keywords

  • SR25990C
  • Platelet Aggregation Inhibitors
  • NSTEACS
03

In context

Lead sponsor

Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged above 20, admitted to hospitals with symptoms suspected to represent an acute coronary syndrome defined as unstable angina or acute MI without ST segment elevation greater than 1 mm are eligible for the study if they meet the following criteria:

    • (1)Clinical history consistent with new onset or worsening pattern of characteristic ischemic chest pain occurring at rest or with minimal exercise (lasting longer than 5 minutes or requiring sublingual nitroglycerin for the relief of pain within 24 hours before registration).
    • (2)Patients who meet either of following criteria

      • changes compatible with new ischemia [e.g. ST depression (at least 1 mm), T wave inversion (at least 2 mm), or hyperacute peaked T waves in 2 contiguous leads].
      • already elevated CK at least twice the or CK-MB or Troponin I or T above the upper limit of normal or positive qualitative test for Troponin T.
    • (3)A percutaneous coronary intervention is planned within 96 hours after the first study drug administration

Exclusion criteria

Exclusion Criteria:

  • A)Factors that affect participation in study:

    • (1)Previous disabling stroke
    • (2)Previous intracranial hemorrhage or hemorrhagic stroke
    • (3)Severe co-morbid condition such that the patient is not expected to survive 1 month
    • (4) Class IV heart failure
    • (5)Uncontrolled hypertension
    • (6)Requirement for use of oral anticoagulants, non study antiplatelet agents (including ticlopidine) or NSAIDs (excluding unum sumatur), during study period,
  • B)Factors related to ASA and/or ticlopidine treatment:

    • (1)Use of ticlopidine within 1 week prior to randomization
    • (2)History of ASA or ticlopidine intolerance or allergy
    • (3) to ASA or ticlopidine
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
800 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of effficacy and safety events

Secondary outcomes

  1. Incidence of efficacy or safety events, adverse events, adverse drug reactions and bleeding events・

07

Study locations

1 site
  • Sanofi-Aventis
    Tokyo, Japan
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 25, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00325390
Lead sponsor
Sanofi
First posted
May 12, 2006
Start date
Jul 2004
Last update
Mar 25, 2009

Study contacts

Yuko HARADA
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clopidogrel

Start the discussion